Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Durable Clinical Activity to the AKT Inhibitor Ipatasertib in a Heavily Pretreated Patient With an AKT1 E17K Mutant Metastatic Breast Cancer.

Clinical breast cancer - 1 Jun 2021

Bose Sminu, Kalinsky Kevin

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Cell Line, Tumor
Share to Mutation
Share to Piperazines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Proto-Oncogene Proteins c-akt

Share to Pyrimidines

Share to Signal Transduction

Source

Identifiers

PMID: 33177006
DOI: 10.1016/j.clbc.2020.10.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Durable Clinical Activity to the AKT Inhibitor Ipatasertib in a Heavily Pretreated Patient With an AKT1 E17K Mutant Metastatic Breast Cancer.PMID 33177006Read ↗

Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial.Semantic proximity Read ↗

Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K.Semantic proximity Read ↗

Tumor-Agnostic AKT Inhibition: Is It Time to AKT?Semantic proximity Read ↗

Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer.Semantic proximity Read ↗

Patient with Lobular Carcinoma of the Breast and Activating AKT1 E17K Variant.Semantic proximity Read ↗

New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer.Semantic proximity Read ↗

AKT Inhibition in Solid Tumors With AKT1 Mutations.Semantic proximity Read ↗

Characteristics and Outcome of AKT1 E17K-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry.Semantic proximity Read ↗

PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.Semantic proximity Read ↗

Alpelisib to treat breast cancer.Semantic proximity Read ↗

A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors.Semantic proximity Read ↗

A systematic molecular and pharmacologic evaluation of AKT inhibitors reveals new insight into their biological activity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.